Seminoma natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
| (23 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Seminoma}} | {{Seminoma}} | ||
{{CMG}}{{AE}}{{ | {{CMG}}{{AE}}{{S.G.}} | ||
==Overview== | ==Overview== | ||
Common complications of seminoma include recurrence, [[Lymph node metastases|lymph node metastasis]], distant [[metastasis]], and secondary [[malignancies]]. [[Prognosis]] is generally good for all stages with greater than 90% cure rate. Seminoma grows slower than non-seminomatous [[germ cell]] [[Tumor|tumors]]. The International Germ Cell Cancer Consensus Group divides seminoma into two [[prognosis]] groups: good and intermediate. The [[Symptom|symptoms]] of seminoma usually develop in the second to forth decade of life (15-35 years), and start with [[Symptom|symptoms]] such as a painless [[Testicle|testicular]] [[lump]], [[abnormal]] [[semen]] [[analysis]], possibly an [[Acute (medicine)|acute]] onset [[testicular]] [[pain]]. | |||
==Natural History== | |||
* | == Natural History == | ||
*The [[Symptom|symptoms]] of seminoma usually develop in the second to forth decade of life (15-35 years), and start with [[Symptom|symptoms]] such as a painless [[Testicle|testicular]] [[lump]], [[abnormal]] [[semen]] [[analysis]], possibly an [[Acute (medicine)|acute]] onset [[testicular]] [[pain]].<ref name="pmid21819630">{{cite journal |vauthors=Boujelbene N, Cosinschi A, Boujelbene N, Khanfir K, Bhagwati S, Herrmann E, Mirimanoff RO, Ozsahin M, Zouhair A |title=Pure seminoma: a review and update |journal=Radiat Oncol |volume=6 |issue= |pages=90 |date=August 2011 |pmid=21819630 |pmc=3163197 |doi=10.1186/1748-717X-6-90 |url=}}</ref> | |||
*Seminoma grows slower than non-seminomatous [[germ cell]] [[Tumor|tumors]]. | |||
==Complications== | ==Complications== | ||
Common complications of seminoma include:<ref name=Testicularseminomaradiopaediafhg>Testicular seminoma. Dr Marcin Czarniecki and Dr Andrew Dixon et al. Radiopaedia 2016. http://radiopaedia.org/articles/testicular-seminoma-1. Accessed on March 3, 2016</ref> | Common [[Complication (medicine)|complications]] of seminoma include:<ref name="Testicularseminomaradiopaediafhg">Testicular seminoma. Dr Marcin Czarniecki and Dr Andrew Dixon et al. Radiopaedia 2016. http://radiopaedia.org/articles/testicular-seminoma-1. Accessed on March 3, 2016</ref> | ||
*Recurrence | *Recurrence | ||
*Lymph node metastasis | *[[Lymph node metastases|Lymph node metastasis]] | ||
*Distant metastasis | *Distant [[metastasis]] | ||
*Increased risk of seminoma in the remaining testicle | *Increased risk of seminoma in the remaining [[testicle]] | ||
*Increased risk of other cancers ( | *Increased risk of other [[Cancer|cancers]] (second [[malignancies]]) | ||
:*[[Mesothelioma]] and [[lung cancer|cancer of the lung]] | :*[[Mesothelioma]] and [[lung cancer|cancer of the lung]] | ||
:*[[Colon cancer]] | :*[[Colon cancer]] | ||
| Line 23: | Line 25: | ||
==Prognosis== | ==Prognosis== | ||
* | *[[Prognosis]] for stage I is excellent, and the survival rate of [[Patient|patients]] with seminoma for satgr I is approximately 100%.<ref name="pmid26893743">{{cite journal |vauthors=Dong W, Gang W, Liu M, Zhang H |title=Analysis of the prognosis of patients with testicular seminoma |journal=Oncol Lett |volume=11 |issue=2 |pages=1361–1366 |date=February 2016 |pmid=26893743 |pmc=4734256 |doi=10.3892/ol.2015.4065 |url=}}</ref><ref name="HoneckerAparicio2018">{{cite journal|last1=Honecker|first1=F|last2=Aparicio|first2=J|last3=Berney|first3=D|last4=Beyer|first4=J|last5=Bokemeyer|first5=C|last6=Cathomas|first6=R|last7=Clarke|first7=N|last8=Cohn-Cedermark|first8=G|last9=Daugaard|first9=G|last10=Dieckmann|first10=K -P|last11=Fizazi|first11=K|last12=Fosså|first12=S|last13=Germa-Lluch|first13=J R|last14=Giannatempo|first14=P|last15=Gietema|first15=J A|last16=Gillessen|first16=S|last17=Haugnes|first17=H S|last18=Heidenreich|first18=A|last19=Hemminki|first19=K|last20=Huddart|first20=R|last21=Jewett|first21=M A S|last22=Joly|first22=F|last23=Lauritsen|first23=J|last24=Lorch|first24=A|last25=Necchi|first25=A|last26=Nicolai|first26=N|last27=Oing|first27=C|last28=Oldenburg|first28=J|last29=Ondruš|first29=D|last30=Papachristofilou|first30=A|last31=Powles|first31=T|last32=Sohaib|first32=A|last33=Ståhl|first33=O|last34=Tandstad|first34=T|last35=Toner|first35=G|last36=Horwich|first36=A|title=ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up|journal=Annals of Oncology|volume=29|issue=8|year=2018|pages=1658–1686|issn=0923-7534|doi=10.1093/annonc/mdy217}}</ref> | ||
*[[Prognosis]] for stage II is generally good, the 5-year mortality survival rate of [[Patient|patients]] with satge II of seminoma is approximately 97%. | |||
*[[Prognosis]] for stage III is generally good, the 5-year mortality survival rate of [[Patient|patients]] with satge III of seminoma is approximately 85%. | |||
| | |||
| | |||
|- | |||
| | |||
| | |||
==References== | ==References== | ||
Latest revision as of 13:34, 15 May 2019
|
Seminoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Seminoma natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Seminoma natural history, complications and prognosis |
|
FDA on Seminoma natural history, complications and prognosis |
|
CDC on Seminoma natural history, complications and prognosis |
|
Seminoma natural history, complications and prognosis in the news |
|
Blogs on Seminoma natural history, complications and prognosis |
|
Risk calculators and risk factors for Seminoma natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]
Overview
Common complications of seminoma include recurrence, lymph node metastasis, distant metastasis, and secondary malignancies. Prognosis is generally good for all stages with greater than 90% cure rate. Seminoma grows slower than non-seminomatous germ cell tumors. The International Germ Cell Cancer Consensus Group divides seminoma into two prognosis groups: good and intermediate. The symptoms of seminoma usually develop in the second to forth decade of life (15-35 years), and start with symptoms such as a painless testicular lump, abnormal semen analysis, possibly an acute onset testicular pain.
Natural History
- The symptoms of seminoma usually develop in the second to forth decade of life (15-35 years), and start with symptoms such as a painless testicular lump, abnormal semen analysis, possibly an acute onset testicular pain.[1]
- Seminoma grows slower than non-seminomatous germ cell tumors.
Complications
Common complications of seminoma include:[2]
- Recurrence
- Lymph node metastasis
- Distant metastasis
- Increased risk of seminoma in the remaining testicle
- Increased risk of other cancers (second malignancies)
Prognosis
- Prognosis for stage I is excellent, and the survival rate of patients with seminoma for satgr I is approximately 100%.[3][4]
- Prognosis for stage II is generally good, the 5-year mortality survival rate of patients with satge II of seminoma is approximately 97%.
- Prognosis for stage III is generally good, the 5-year mortality survival rate of patients with satge III of seminoma is approximately 85%.
References
- ↑ Boujelbene N, Cosinschi A, Boujelbene N, Khanfir K, Bhagwati S, Herrmann E, Mirimanoff RO, Ozsahin M, Zouhair A (August 2011). "Pure seminoma: a review and update". Radiat Oncol. 6: 90. doi:10.1186/1748-717X-6-90. PMC 3163197. PMID 21819630.
- ↑ Testicular seminoma. Dr Marcin Czarniecki and Dr Andrew Dixon et al. Radiopaedia 2016. http://radiopaedia.org/articles/testicular-seminoma-1. Accessed on March 3, 2016
- ↑ Dong W, Gang W, Liu M, Zhang H (February 2016). "Analysis of the prognosis of patients with testicular seminoma". Oncol Lett. 11 (2): 1361–1366. doi:10.3892/ol.2015.4065. PMC 4734256. PMID 26893743.
- ↑ Honecker, F; Aparicio, J; Berney, D; Beyer, J; Bokemeyer, C; Cathomas, R; Clarke, N; Cohn-Cedermark, G; Daugaard, G; Dieckmann, K -P; Fizazi, K; Fosså, S; Germa-Lluch, J R; Giannatempo, P; Gietema, J A; Gillessen, S; Haugnes, H S; Heidenreich, A; Hemminki, K; Huddart, R; Jewett, M A S; Joly, F; Lauritsen, J; Lorch, A; Necchi, A; Nicolai, N; Oing, C; Oldenburg, J; Ondruš, D; Papachristofilou, A; Powles, T; Sohaib, A; Ståhl, O; Tandstad, T; Toner, G; Horwich, A (2018). "ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up". Annals of Oncology. 29 (8): 1658–1686. doi:10.1093/annonc/mdy217. ISSN 0923-7534.